Drug interactions
Avapritinib + Ticlopidine
Severity: Moderate
Avapritinib and Ticlopidine: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Ticlopidine is not a significant CYP3A4 inhibitor, so a clinically relevant increase in avapritinib exposure is unlikely. Avapritinib itself causes intracranial hemorrhage risk and thrombocytopenia, which makes concurrent antiplatelet use worth noting.
What this interaction means in plain words
Avapritinib and Ticlopidine can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Avapritinib belongs to Oncology; Ticlopidine belongs to Cardiovascular.
Why it happens
No established pharmacokinetic mechanism; additive bleeding risk is pharmacodynamic since ticlopidine inhibits platelets and avapritinib can cause thrombocytopenia and bleeding.
What to do
Monitor platelet counts and for bleeding or neurological symptoms during combined use.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Avapritinib and Ticlopidine, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Ticlopidine
Other interactions of Avapritinib
Frequently asked questions
Can I take Avapritinib with Ticlopidine?
MediHelp rates the interaction as moderate. Avapritinib and Ticlopidine can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Ticlopidine is not a significant CYP3A4 inhibitor, so a clinically relevant increase in avapritinib exposure is unlikely. Avapritinib itself causes intracranial hemorrhage risk and thrombocytopenia, which makes concurrent antiplatelet use worth noting.
How serious is the interaction between Avapritinib and Ticlopidine?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor platelet counts and for bleeding or neurological symptoms during combined use.
What other medicines interact with Ticlopidine?
MediHelp also lists interactions of Ticlopidine with, for example, Mavacamten, Abrocitinib, Acetylsalicylic acid. The full list is on the Ticlopidine page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
